NZ751414A - Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof - Google Patents
Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereofInfo
- Publication number
- NZ751414A NZ751414A NZ751414A NZ75141417A NZ751414A NZ 751414 A NZ751414 A NZ 751414A NZ 751414 A NZ751414 A NZ 751414A NZ 75141417 A NZ75141417 A NZ 75141417A NZ 751414 A NZ751414 A NZ 751414A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bcl
- antibody
- inhibitor
- combination
- mor00208
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196184 | 2016-10-28 | ||
| PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ751414A true NZ751414A (en) | 2025-10-31 |
Family
ID=57218739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ751414A NZ751414A (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Country Status (26)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| PL3630177T3 (pl) | 2017-05-31 | 2024-04-08 | Morphosys Ag | Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CA3107085A1 (en) * | 2018-08-31 | 2020-03-05 | Adc Therapeutics Sa | Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| MX2022005032A (es) * | 2019-10-31 | 2022-07-27 | Morphosys Ag | Terapia secuencial anti cumulo de diferenciacion 19 (cd19). |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| MX2007015944A (es) | 2005-06-20 | 2008-03-07 | Medarex Inc | Anticuerpos cd19 y sus usos. |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CN101500930B (zh) | 2006-08-15 | 2012-05-30 | 海德勒利夫特埃姆克莱德股份有限公司 | 对从线的一端悬入海洋环境的负载物提供升沉补偿的装置和方法 |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| ES2616789T3 (es) | 2006-09-22 | 2017-06-14 | Pharmacyclics, Inc. | Inhibidores de tirosina cinasa de Bruton |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| US20100128586A1 (en) | 2008-11-25 | 2010-05-27 | Mediatek Inc. | Method and apparatus for accessing data from disc with linking area |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CA2765080C (en) | 2009-06-24 | 2018-07-17 | The Feinstein Institute For Medical Research | Methods for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| US8543911B2 (en) | 2011-01-18 | 2013-09-24 | Apple Inc. | Ordering document content based on reading flow |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| AU2012296905B2 (en) * | 2011-08-16 | 2017-01-05 | Incyte Corporation | Combination therapy with an anti - CD19 antibody and a purine analog |
| SI2744515T1 (sl) | 2011-08-16 | 2022-05-31 | Morphosys Ag | Kombinirana terapija s protitelesom proti CD19 in dušikovim iperitom |
| CN105793251B (zh) * | 2013-12-05 | 2018-10-12 | 豪夫迈·罗氏有限公司 | 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
| EP3476392A1 (en) * | 2014-02-28 | 2019-05-01 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| ES2876263T3 (es) * | 2014-04-07 | 2021-11-12 | Novartis Ag | Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19 |
| CA2951427A1 (en) | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| IL293714A (en) | 2014-10-20 | 2022-08-01 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| WO2016130902A1 (en) * | 2015-02-12 | 2016-08-18 | Seattle Genetics, Inc. | Combination therapy using a cd19-adc and vincristine |
| RU2727196C2 (ru) | 2015-05-26 | 2020-07-21 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе антитела к cd20 в сочетании с ингибитором bcl-2 и ингибитором mdm2 |
| CA2986175A1 (en) | 2015-05-26 | 2016-12-01 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| MA45124B1 (fr) | 2016-05-30 | 2021-05-31 | Morphosys Ag | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| CN115998859A (zh) | 2016-06-27 | 2023-04-25 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| PL3630177T3 (pl) | 2017-05-31 | 2024-04-08 | Morphosys Ag | Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem |
| US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| MX2021013101A (es) | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| MX2022005032A (es) | 2019-10-31 | 2022-07-27 | Morphosys Ag | Terapia secuencial anti cumulo de diferenciacion 19 (cd19). |
| IL317199A (en) | 2019-10-31 | 2025-01-01 | Morphosys Ag | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| US20210130461A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| CN115956088A (zh) | 2020-06-22 | 2023-04-11 | 莫佛塞斯公司 | 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法 |
| US20220184208A1 (en) | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| KR20240131370A (ko) | 2021-12-22 | 2024-08-30 | 인사이트 코포레이션 | 항-cd19 항체 요법을 위한 치료 패러다임 |
-
2017
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active Active
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 US US16/342,645 patent/US12358983B2/en active Active
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 BR BR112019008244-1A patent/BR112019008244A2/pt unknown
- 2017-10-27 NZ NZ751414A patent/NZ751414A/en unknown
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en not_active Ceased
- 2017-10-27 SM SM20210347T patent/SMT202100347T1/it unknown
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Ceased
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 AU AU2017348624A patent/AU2017348624B2/en active Active
- 2017-10-27 IL IL320372A patent/IL320372A/en unknown
- 2017-10-27 IL IL301786A patent/IL301786B2/en unknown
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125584A patent/JP2024167208A/ja active Pending
- 2024-12-23 AU AU2024287178A patent/AU2024287178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ751414A (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
| MX2022006154A (es) | Combinaciones y sus usos. | |
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| WO2016062722A8 (en) | Combination | |
| CY1122298T1 (el) | Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του | |
| MX2024000300A (es) | Anticuerpos antitau y metodos de uso. | |
| PH12017501318B1 (en) | Anti-transthyretin antibodies | |
| MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
| CY1125148T1 (el) | Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης | |
| IL271266A (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| CY1125122T1 (el) | Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου | |
| EP4360646A3 (en) | Anti-tigit antibodies and methods of use | |
| WO2015153513A8 (en) | Anti-ox40 antibodies and methods of use | |
| MX2019005401A (es) | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| IL263165A (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
| MX2019011423A (es) | Metodos de tratamiento de enfermedades neurodegenerativas. | |
| MX2018000267A (es) | Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. | |
| MY188849A (en) | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor | |
| MX2020002613A (es) | Accionador lineal de alta reduccion impulsado por correas. | |
| MX2017015311A (es) | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. | |
| HK40079976A (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| MY193688A (en) | Anti-transthyretin antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: INCYTE CORPORATION, US Effective date: 20241209 |